Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
14 hedge funds and large institutions have $54.7M invested in Evofem Biosciences, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
27% more funds holding
Funds holding: 11 → 14 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
41% less capital invested
Capital invested by funds: $92.2M → $54.7M (-$37.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$11.2M |
| 2 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$11.2M |
| 3 |
Millennium Management
New York
|
+$3.79M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.86M |
| 5 |
TWMP
Taylor Wealth Management Partners
Boston,
Massachusetts
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$12K |
| 2 |
WAS
WESPAC Advisors SoCal
Pasadena,
California
|
-$3K |
EVFM Hedge Fund Activity: Q2 2018 in Review
14 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2018, worth a combined $54.7M — down 41% from $92.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVFM positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Invesco, adding an estimated $11.2M. The largest seller was Bank of America, exiting entirely with an estimated $12K sold.
- 14 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2018, up from 11 in Q1 2018.
- Funds reported $54.7M of Evofem Biosciences, Inc. Common Stock stock for Q2 2018, down 41% quarter-over-quarter.
- 5 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2018 and 2 closed out, a net change of +3 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2018 was Invesco, an estimated $11.2M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2018 was Bank of America, an estimated $12K sold.
Based on aggregated 13F filings for Q2 2018.